Core Framework & Diagram Why Does Antibiotic Resistance Develop?
July 27, 20261 Min Read Why Is Children’s Immunity Different?
July 27, 2026The drugs exist — so why can some bacteria still not be killed?
—— How superbugs evolved, and why this arms race is directly relevant to you.
I. A number that should make your spine tingle: 700,000 deaths per year
Globally, approximately 700,000 people die annually from antibiotic-resistant bacterial infections.
This figure comes from a 2016 authoritative report prepared for the UK government (the O'Neill Report), which simultaneously predicted: if current trends continue unchanged, by 2050 this figure will rise to ten million per year — at that point surpassing cancer as the world's leading cause of death.
This isn't a distant future scenario. In Malaysia, multidrug-resistant (MDR) infections are already a real daily challenge for clinicians. Every surgery, every hospitalization, every invasive procedure carries genuine risk of resistant bacterial infection.
The question is: why do antibiotics fail? Many people think antibiotic failure is because 'the dose was insufficient' or 'the drug didn't match the infection.' That's only part of the answer. The more fundamental reason is that the race between bacterial evolution speed and humanity's rate of new antibiotic development is being won by the bacteria.
2. How bacteria learn to fight antibiotics: Darwin's selection playing out in twenty minutes
Understanding antibiotic resistance starts with a fact that surprises many people: bacteria reproduce approximately every twenty minutes.
In human time perception, twenty minutes accomplishes nothing. But for bacteria, twenty minutes is a complete life generation — enough time for natural selection to complete one round of screening.
In a typical infection scenario, your body may contain hundreds of millions to billions of bacteria. Within this enormous population, random genetic mutations exist — the unavoidable error rate in all life's replication processes. Most mutations are harmful or neutral for the bacteria, but occasionally a mutation happens to give a bacterium a capacity to reduce sensitivity to a particular antibiotic.
Without antibiotics, this mutation gives the bacterium no advantage — bacteria with it compete alongside ordinary bacteria with no numerical distinction.
But when you start taking antibiotics, everything changes. Most normal bacteria are killed by the antibiotic; that bacterium carrying the resistance mutation survives. And with all other bacteria dead, nutrients become abundant — the surviving bacterium begins rapidly reproducing. Every twenty minutes a generation, within hours producing large numbers of offspring — and all of these offspring carry that resistance mutation.
This is Darwin's natural selection playing out in real time at the microbial scale. Antibiotics don't make bacteria 'learn' resistance — they select out the originally rare resistant bacteria, giving them the opportunity to monopolize resources and rapidly expand.
Even more concerning is horizontal gene transfer: bacteria can directly 'pass' resistance genes to other bacteria — even different species — via plasmids (small circular DNA). This allows resistance genes to spread rapidly throughout bacterial populations without waiting for generational turnover.
3.Bacteria's four weapons against antibiotics
Weapon one: enzyme degradation
The most typical example is β-lactamase — an enzyme bacteria produce that specifically destroys the core chemical structure (the β-lactam ring) of penicillins and cephalosporins. Once this ring is broken, the antibiotic loses its activity. Bacteria producing extended-spectrum β-lactamases (ESBL) can resist almost all ordinary penicillins and cephalosporins, causing serious problems in hospital-acquired infections.
Weapon two: modifying the antibiotic's target
Penicillin's mechanism is binding to proteins essential for bacterial cell wall synthesis (penicillin-binding proteins, PBP). MRSA's (methicillin-resistant Staphylococcus aureus) resistance mechanism is producing a mutant PBP (PBP2a) with extremely low binding affinity for penicillin-type antibiotics — the antibiotic can't effectively bind, and the bacterium continues normally synthesizing its cell wall and growing.
Weapon three: efflux pumps
Some bacteria evolved highly efficient 'pump proteins' in their cell membranes that actively pump out antibiotics that have entered the cell, maintaining internal antibiotic concentrations below effective bactericidal doses. This mechanism is often effective against multiple structurally different antibiotics and is an important contributor to multidrug resistance.
Weapon four: reduced permeability
Some Gram-negative bacteria (like Pseudomonas aeruginosa) reduce 'porin' expression in their outer membranes, making the membrane less permeable and physically blocking multiple antibiotic molecules from entering the cell. Combined with efflux pumps, reduced permeability can create extremely strong multidrug resistance. MRSA, carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii — these 'superbugs' often use multiple resistance mechanisms simultaneously, leaving treatment options extremely limited or even nonexistent.
4. Antibiotic overuse: a collective behavior problem everyone participates in
Antibiotic resistance is a classic 'tragedy of the commons' problem: any single individual's unnecessary antibiotic use carries almost negligible personal risk; but everyone's combined overuse creates a silent catastrophe at the entire microbial ecosystem level.
Using antibiotics for colds
The vast majority of colds are viral (primarily rhinovirus, adenovirus) — antibiotics are completely ineffective against viruses. But many people (and many doctors) use antibiotics for colds under the rationale of 'preventing bacterial superinfection.' This approach lacks adequate evidence support, yet kills large numbers of beneficial gut bacteria, disrupts microbiome diversity, and selects out resistant bacteria.
Stopping antibiotics early when symptoms improve
This is the most common and most insidious form of overuse. Symptom improvement doesn't mean bacteria are completely cleared — stopping early often removes the 'selection pressure' when bacterial numbers are still relatively high. The surviving bacteria with naturally stronger resistance have the chance to breathe and expand.
Agricultural and livestock antibiotic use
Approximately fifty to sixty percent of global antibiotic production is used in agriculture — for promoting livestock growth and prophylactic treatment, not genuine disease treatment. This creates large amounts of low-concentration antibiotic exposure in soil, water, and the food chain, an important source of resistance gene spread in the environment.
5. What can we actually do facing superbugs?
For individuals, the most important thing: don't use antibiotics without a physician explicitly diagnosing a bacterial infection. Colds, sore throats, and most coughs are viral and don't need antibiotics. If a doctor does prescribe antibiotics, take the complete course — don't stop when 'feeling better.' Antibiotic course lengths are designed based on the time needed to sufficiently clear the pathogen, not 'time until symptoms disappear.' These two typically have a gap of several days — and during that gap, resistant bacteria most easily seize the opportunity to expand.
Vaccination is another important strategy against resistant bacteria that's often overlooked. Every successfully prevented infection is one instance where antibiotics aren't needed; and every reduction in antibiotic use contributes to slowing resistance spread. For bacteria originally requiring large amounts of antibiotics to control — Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitidis — widespread vaccination has already significantly reduced clinical infection rates and associated antibiotic use.
At the medical research level, phage therapy (using viruses that specifically kill bacteria to treat resistant infections), antimicrobial peptides, and CRISPR-targeted gene editing are among the most promising alternative directions. Phage therapy has produced encouraging early results in some 'no viable antibiotic' superbug infection cases as compassionate use — but until these technologies mature, 'reducing unnecessary antibiotic use' remains the most effective, lowest-cost defense line that everyone can participate in today.
Frequently Asked Questions